In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

UK General Election Misjudgment: Dismay For May Who Finds The Politics Of Greed Don't Pay

The smart money had increasingly been on a hung parliament in the UK, with the ruling Conservative party being punished for several policy slip-ups, perceived dithering by Prime Minister Theresa May and her insistence on a clean and hard Brexit led by her alone. The June 8 election did not need to be called, and today, May is ruing the fact that she has lost both the party's absolute majority and her mandate to lead on a hard Brexit.

United Kingdom Brexit Medical Device
Advertisement

Latest From Market Access

2017 Fair Pricing Forum: The Message For Pharma CEOs

Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.

BioPharmaceutical Market Access

EU Medtechs Keep Open Mind On HTA Options In Wider Market Access Plan

Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.

Health Technology Assessment Policy & Regulation

Schilsky On ASCO 2017: The “You” Factor In Cancer Care

ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.

BioPharmaceutical Cancer

WannaCry Cybersecurity Alert Shows Medtech Software Must Look Beyond Quick Fixes

Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.

Digital Health Commercial

CAR-T Cancer Drugs Front And Center At ARM Investor Day

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

Regenerative Medicine Commercial

Free And Open: The Next Wave In Clinical Trial Data?

Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.

Clinical Trials Platform Technologies
See All
UsernamePublicRestriction

Register